Caution, This content is for veterinary professionals.


Part of a streamlined range of vaccines with a straightforward protocol to provide excellent protection against core feline diseases

Leucogen® is the World’s first recombinant subunit vaccine containing purified p45 FeLV-envelope antigen identified as the most important antigen for stimulating immunity to FeLV.

Product Features & Benefits: 

  • Provides targeted effective antigenic challenge 

  • 3 year duration of immunity

  • Proven efficacy and safety2,3

  • Recombinant subunit FeLV vaccine

  • Protects against all 3 subgroups of FeLV


Presentations Available: 

Available in 10 or 50 doses.


Available UK & Ireland logo.jpg

Use medicines responsibly.
Further information is available on the SPC or on request from Virbac Ltd.

1. Summary of Product Characteristics. 
2. Jarrett O et al. Comparative studies of the efficacy of a recombinant feline leukaemia, The Veterinary Record 1996; 138:7-11. 
3. Lutz H. Comparative studies of the effi cacy of two leukaemia virus vaccines. Proceedings of the 4th European FECAVA Congress 1998.